SYNTHESIS OF ASSIGNED STRUCTURE OF CAIROMYCIN A, 6-ISOPROPYL-2,5-DIKETOPIPERAZINE-3-ACETIC ACID AND ITS B-LACTAM ANALOGUE N'- (3-METHYL-1-HYDROXYBUTYR-2-YL) AZETIDIN-2-ONE-4-CARBOBOXIMIDE

Faiq H. S. Hussain*

Dept. of Medical Analysis, Faculty of Science, Tishk International University, Erbil, Kurdistan Region-Iraq (faiq.hussain@ishik.edu.iq)

Received: Sep., 2019 / Accepted: Dec., 2019 / Published: Dec., 2019

https://doi.org/10.105271/jouoz.2019.7.4.638

ABSTRACT:
In the present investigation, the research carried out into the total synthesis of the assigned structure of cairomycin A, 6-isopropyl-2,5-diketopiperazine-3-acetic acid from its precursors L-valine and L-aspartic acid, and its analogue N’-(3-methyl-1-hydroxybutyr-2-yl)azetidin-2-one-4-carboximide from 4-vinylazetidin-2-one through two different sequence reactions. Structures of the synthesized products were identified by using chemical and physical methods such as elemental analysis, IR, 1H-NMR and MS. The obtained results were compared with those reported, it was found that neither of the synthesized compounds was Cairomycin A.

KEYWORDS: Cairomycin A, 2,5-Diketopiperazine, β-Lactam, Azetidine, Antimicrobial.

1. INTRODUCTION

2,5-Diketopiperazine (1), is a smallest class of cyclopeptide, which produced from the condensation and cyclization of two amino acids (Dinsmore et al 2002). Diketopiperazine and its derivatives are known to be associated with broad spectrum of biological activity like antitumor (Nicholson et al 2006), antiviral (Sinha et al 2001), antifungal (Houston et al 2004), and antibacterial (Abraham 2005). However, many synthetic methods are available mainly based on the dipeptide reactions by conventional methodology from α-amino acids (Fischer 2003; O’Neill et al 2007; Sun 2014).

Shimi and Fathey isolated a cyclic antibiotic from the fermentation of Streptomyces sp. strain As-C-19 which obtained from the soil of Cairo (Shimi and Fathey 1981), this antibiotic was designated as 6-isopropyl-2,5-diketopiperazine-3-acetic acid, cairomycin A (2) which is potent peptide against Gram positive bacteria. Acid hydrolysis of this isolated diketopiperizene afforded two amino acids, L-valine and L-aspartic acid.

The designed structure (2) was prepared by reported literature procedure from t-butylxcarbonyl L-valin and L-aspartic acid dibenzyl ester-p-toluene sulfonate (Kumar A. et al 1985).

Here, we propose our design strategy to record the total synthesis of compound (2) from its precursors L-aspartic acid and L-valine. So, the aim is to follow a step by step tuning of the diketopeprizene structure on the one hand, and compare its spectroscopic data, physical properties with those reported, on the other hand, in order to get the required information on the structure for the desired compound, with the help of suitable and corroborating biological evaluations.

2. EXPERIMENTAL

2.1 Reagents and Techniques:
Melting points were determined using Gallenkamp melting point apparatus and uncorrected. IR spectra were obtained using a Perkin-Elmer 197 instrument. 1H-NMR spectra were recorded using Perkin-Elmer R34 (220 MHz) instrument with (TMS) as a standard. Mass spectra were determined using Kratos MS45 instrument. Most of solvents were distilled prior to use. All fine chemicals were purchased from Sigma-Aldrich and used without any further purification.

2.2 Synthetic Procedures: Preparation of carbobenzyloxy valine (4)
To a solution of L-valine (5.85 g, 50 mmol) in an aqueous solution of sodium hydroxide (12.6 ml, 4N) at 0°C were added concurrently during 1 h carbobenzoxy chloride (10.7 ml, 12.78 mmol) and sodium hydroxide solution (16.6 ml, 4N) with vigorous stirring. The resulting solution was acidified with hydrochloric acid (1M) and the viscous solution that formed was extracted with vigorous stirring into ethyl acetate (4x100 ml). The combined extracts were cooled to 0°C and extracted with ice-cold 10% aqueous sodium carbonate solution (3x100 ml). The oily product which separated upon acidification of the combined sodium carbonate extracts solidified on standing overnight in the cold. The obtained product was filtered off, washed with cold water and dried (over P₂O₅) in vacuo to afford the pure carbobenzyloxy valine (10.3 g, 82 %) as a white solid; m.p: 54-55 °C. IR (cm⁻¹): 3400, 3200-2750, 1740, 1650. 1H-NMR (CDCl₃); δ= 0.9 (3H, d, J 4.0 Hz, CH₃); 1.05 (3H, d, J 4.0 Hz, CH₃); 2.2 (1H, m, CH(CH₃)₂); 4.3 (1H, m, NCHCO₂); 5.15 (2H, s, OCH₂); 5.5 (1H, m, NH); 7.4 (5H, s, Ph); 10.6 (1H, s, OH). MS: m/z: 251 (M⁺), 206 (M⁺-CO₂H), 162 (PhCH₂OCO-N=═C’H), 108 (PhCH₂OH), 91 (PhCH₂⁺). Anal.
Preparation of succinimido N-(N-carboxy-L-valyl)oxybenzyl ester (5)

To an ice-bath cooled mixture of carbenzoxy valine (10.04 g, 40 mmol) and N-hydroxysuccin-imide (4.6 g, 40 mmol) in dioxane (10 ml) was added N,N'-dicyclohexylcarbodiimide (8.24 g, 40 mmol). A white precipitate formed immediately and the mixture was allowed to stand overnight in a refrigerator (approximately -10°C). The dicyclohexylurea was filtered off and washed with dioxane (10 ml); when the filtrate was concentrated and the residue was triturated with ether, a white solid crystallized out on cooling. Recrystallization of crude product from isopropanol gave the desired product (11.2 g, 80%) as a white crystalline solid; m.p.: 136 °C. I.R (cm−1): 3290, 3050, 1750, 1570. 1H-NMR ((CD3)2CO): δ: 1.05 (6H, d, J = 6.0 Hz, 2 CH3); 2.3 (1H, m, CH(CH3)2); 2.8 (4H, s, 2CH2); 4.5 (1H, m, NCHCO2CH(CH3)2); 5.05 (2H, s, OCH3); 6.9 (1H, br., NH); 7.3 (5H, s, Ph). MS: m/z; 348 (M+), 206 (M–MeO2CCH(NH)CH2CO2Me), 162 (PhCH2O–CN=C–H), 91 (PhC=H), 83 [(CH2)4C=O–NH2–C=O]. Anal. calc. for C14H17N2O4: C = 57.8, H = 6.6, N = 7.1%, found: C = 57.8, H = 6.9, N = 7.1%.

Preparation of 6-isopropyl-2,5-diketopiperazine-3-methyl acetate (10)

The dipeptide amino acid (9) (4.0 g, 10 mmol) was dissolved in 0.1 M acetic acid-butan-2-ol (200 ml) and 10% palladium on charcoal (0.2 g) was added. The mixture was stirred until the atmosphere of hydrogen for 2h after which it was filtered through a celite layer, and a white solid compound crystallized out of the clear colorless solution. The mixture was refluxed for 3h to ensure that cyclization had taken place. The white crystals which formed by concentrating the solution were filtered off and dried over P2O5. The desired cyclized compound (242) was obtained (2.13 g, 92%) as a white crystalline solid; m.p: 229-231 °C. I.R (cm−1): 3200, 3050, 1750, 1670 (br.). 1H-NMR (DMSO-d6): δ: 0.84 (3H, d, J = 6.0 Hz, CH3); 0.95 (3H, d, J = 6.0 Hz, CH); 2.2 (1H, m, CH2CH2); 2.66 and 2.71 (each 1H, d, J = 4.0 Hz, CH); 3.6 (3H, s, OCH3); 3.78 (1H, m, CH(CH2)2); 8.04 (1H, s, NH); 8.09 (1H, s, NH). MS: m/z: 228 (M+), 213 (M–CH3), 197 (M–OCH3), 112 (M–CH2(Ph) and CH2OCH2CH3). Anal. calc. for C14H18N2O4: C = 52.6, H = 7.0, N = 12.3%, found: C = 52.7, H = 6.8, N = 12.3%.

Preparation of 6-isopropyl-2,5-diketopiperazine-3- acetic acid (2)

A solution of 6-isopropyl-2,5-diketopiperazine-3-methyl acetate (10) (1.14 g, 5 mmol) and 10% aqueous potassium hydroxide solution (2.6 ml) in methanol (12 ml) was warmed to obtain a clear solution which was stirred overnight at room temperature. The potassium salt was formed as a white solid compound. After the methanol was evaporated, the residue was dissolved in water (15 ml) and acidified with dilute hydrochloric acid. A white solid crystallized upon acidification obtained which was filtered off (0.8 g, 75%). An analytical pure sample was produced by sublimation (120-130°C, 0.5 mmHg); m.p: 222-224 °C. I.R (cm−1): 3200, 3550-2200, 1725, 1670-1620 (br.). 1H-NMR (DMSO-d6): δ: 0.83 (3H, d, J = 6.0 Hz, CH3); 0.91 (3H, d, J = 6.0 Hz, CH); 2.1 [1H, m, CH(CH2)2]; 2.65 and 2.7 (each 1H, d, J = 4.0 Hz, CH2); 3.58 [1H, m, CH(CH2)2]; 4.11 (1H, m, CH(CH2)2); 8.04 (1H, s, NH); 8.12 (1H, s, NH). MS: m/z: 114 (M+), 199 (M–CH3), 172 (M–CH2(Ph) and CO2H). Anal. calc. for C14H18N2O4: C = 50.5, H = 6.5, N = 13.1%, found: C = 50.6, H = 6.6, N = 13.3%.

Preparation of 4-vinylazetidine-2-one (15) (Brennan et al. 1980)

Butadiene (10 ml, 120 mmol) was liquefied at -78 °C in pressure tube and diluted with dry ether (10 ml). To this solution anhydrous sodium carbonate (0.5 g) was added and followed by chlorosulphonylisocyanate (5.5 ml, 8.97 g, 60 mmol). The tube was allowed to come to room temperature and after 16h the golden colored solution was poured cautiously into a vigorously stirred mixture of sodium sulfite (40 g), potassium hydrogen phosphate (24 g) and ice (100 g) in water (100 ml). After stirring with ether (100 ml) for 30 minutes the organic layer was separated and the aqueous layer was re-extracted with ether (3 x 100 ml). The bulked ether was dried (MgSO4) and concentrated in vacuo to yield the product as a pale yellow liquid (5.32 g, 87%). An analytical sample was obtained by distillation.
Mixture was poured in 45 mmol), followed by t
To a
Preparation of 1
acetate (4 x 25 ml), the combined organic extract was dried
n
mixture was stirred at room temperature for 10 h under
added 4
potassium permanganate (0.14 g, 0.89 mmol) and sodium
To a solution of potassium
evaporated. No oxidized product was obtained.
combined organic extracts were dried (MgSO

temperature. The reaction mixture was poured into
added and the mixture was stirred for 8 h at room
DMF (7 ml), pyridinium dichromate (3.5 equivalent) was
dissolved in methanol (30 ml), cooled to
the mixture was stirred for 8 h at room
discharged by dropwise addition of 30 % hydrogen
1.5 h at room t
permanganate (1.7 g, 11 mmol) in water (30 ml) was
The prepared ozonide, as described above, was dissolved in
pressure (no heating) and the residue was dissolved in
water (30 ml); acidified with 1M hydrochloric acid
and extracted with ethyl acetate (50 ml). The organic
phase was separated, dried (Na2SO4) and evaporated. No characterizable product was obtained.

2. In dichloromethane
The procedure was similar to the one used above, no required product could be isolated.

B. With ozone-pyridinium dichromate (Corey and Schmidt, 1979)
The prepared ozoneide, as described above, was dissolved in DMF (7 ml), pyridinium dichromate (3.5 equivalent) was
added and the mixture was stirred for 8 h at room temperature. The reaction mixture was poured into water (20 ml)
and extracted with ethyl acetate (2 x 15 ml). The combined organic extracts were dried (MgSO4) and evaporated.
No oxidized product was obtained.

C. With periodate-permanganate (Lemieux and Rudloff, 1955)
To a solution of potassium carbonate (1.84 g, 13 mmol), potassium permanganate (0.14 g, 0.89 mmol) and sodium
meta-periodate (11.4 g 53.3 mmol) in water (30 ml), was added 4-vinyl azetidin-2-one (245) (0.6 g, 6.6 mmol) and the
mixture was stirred at room temperature for 10 h under nitrogen atmosphere. The mixture was extracted with ethyl
acetate (4 x 25 ml), the combined organic extract was dried (MgSO4) and evaporated in vacuo. No desired product was obtained.

Preparation of 1-(t-butyldimethylsilyl)-4-vinylazetidin-2-
one (17)
To a solution of 4-vinylazetidin-2-one (4.0 g, 41 mmol) in
DMF (50 ml) at 0°C was added triethylamine (6.34 ml, 4.6 g, 45 mmol), followed by t-butyldimethylsilyl chloride (6.75 g, 45 mmol) and the mixture was stirred for 1 h. The reaction mixture was poured into ether (100 ml) and extracted with water (5 x 100 ml) followed by brine (30 ml). The organic layer was separated, dried over MgSO4 and concentrated
under reduced pressure to give the product as a straw-colored
liquid (7.75 g, 89%); I.R (cm

Preparation of 1-(t-butyldimethylsilyl)-4-hydroxy carbonyl-
azetidin-2-one (18)
Powdered potassium permanganate (6.0 g, 38 mmol) was added over 2 h to an acetone solution (25 ml) of 1-t-buty1-4-
vinylazetidin-2-one (2.11 g, 10 mmol) containing powdered
sodium bicarbonate (0.35 g) at 7°C and the mixture was
vigorously stirred for 4 h. Water (20 ml) was added to the residue after evaporating off the acetone. The solution was acidified with 1M sulfuric acid and solid sodium bisulfite (5.0 g) was added. The resulting clear solution was extracted with ethyl acetate (3 x 50 ml) after which the organic phase was separated, dried (MgSO4) and evaporated in vacuo. Recrystallization of the residue from toluene provided the pure product (1.95 g, 85%) as a white solid; m.p: 130-131°C. I.R. (cm

Preparation of 1-(t-butyldimethylsilyl)-4-(succinimido-N-
oxycarbonyl) azetidin-2-one (19)
N,N-Dicyclohexylcarbodiimide (1.66 g, 8 mmol) was added to an ice-bath cooled solution of 1-(t-buty1dimethylsilyl)-4-hydroxy
carbonylazetidin-2-one (18) (1.83 g, 8 mmol) and N-hydroxy-
succinimide (0.92 g, 8 mmol) in dry dioxane (4 ml). The mixture
was allowed to stand overnight in the refrigerator (approximately
-10°C) after which dicyclohexylurea was filtered off and washed
with dioxane (4 ml). The clear filtrate was concentrated in vacuo to a colorless oil which crystallized on trituration under
petroleum ether (b.p. 40-60°C) with cooling to yield the product
as a white crystalline solid. Recrystallization from isopropanol
gave the pure desired product (2.52 g, 97%); m.p: 86-88°C. I.R
(cm

Preparation of L-valine benzyl ester-p-toluene sulfonate salt
(20)
Into a round-bottomed flask were placed L-valine (5.85 g, 50
mmol), p-toluene sulfonic acid monohydrate (9.7 g, 51 mmol)
benzyl alcohol (20 ml), and benzene (10 ml). The mixture
was heated under reflux, with the liberated water being removed
azeotropically and trapped with the aid of a Dean-Stark
apparatus. A clear solution was obtained soon after reflux began.
When water (about 2 ml) was distilled off (4 h) the reaction
mixture was permitted to cool to room temperature, and a mixture
of benzene (50 ml) and dry ether (80 ml) was added. After standing for 2 h at 4 °C, the crystalline benzyl valinate-p-toluene sulfonate was filtered off, washed with anhydrous ether, and recrystallized from methanol-ether, gave the product (27 g, 83 %) as a white solid compound; m.p: 154-156 °C. 1 R (cm-1): 3250-2500, 1745, 1600, 1380, 1170, 820. 1H-NMR (CDCl3): δ = 0.85 and 0.89 (each 3H, d, J = 6.0 Hz, 2 CH3); 2.17 (1H, m, CH(CH3)): 2.32 (3H, s, PhCH3): 3.93 (1H, m, CHN): 5.0 and 5.15 (each 1H, d, J = 10.8 Hz, H2Ph): 7.12 and 7.81 (each 2H, d, J = 8.0 Hz, C6H4): 7.5 (5H, s, C6H5): 8.24 (3H, m, NH2). MS: m/z: 208 (M+-C4H8SO2), 172 (C2H5SO2), 116 (M+-C2H5SO2 and PhCH3), 91 (PhCH2). Anal. calc. for C17H13O2N2S: C = 60.2, H = 6.6, N = 9.2 %, found: C = 60.1, H = 6.6, N = 9.4 %. The residue was evaporated. Chromatography of the residue (acetone/ethyl acetate 1:1) provided the yellow product. Evaporation, washed with anhydrous ether, and recrystallized from methanol-ether, gave the product (27 g, 76 %) as yellow solid compound; m.p: 147-148 °C (lit: 148-150 °C). 1H-NMR (CDCl3): δ = 0.60 and 0.63 (each 3H, d, J = 6.0 Hz, 2 CH3); 2.17 (1H, m, CH(CH3)): 2.32 (3H, s, PhCH3): 3.93 (1H, m, CHN): 5.0 and 5.15 (each 1H, d, J = 10.8 Hz, H2Ph): 7.12 and 7.81 (each 2H, d, J = 8.0 Hz, C6H4): 7.5 (5H, s, C6H5): 8.24 (3H, m, NH2). MS: m/z: 3275, 1740, 1650, 1540. 1H-NMR (DMSO-d6): δ = 0.94 and 1.08 (each 3H, d, J = 6.0 Hz, 2 CH3); 2.17 (1H, m, CH(CH3)): 2.32 (3H, s, PhCH3): 3.93 (1H, m, CHN): 5.0 and 5.15 (each 1H, d, J = 10.8 Hz, H2Ph): 7.12 and 7.81 (each 2H, d, J = 8.0 Hz, C6H4): 7.5 (5H, s, C6H5): 8.24 (3H, m, NH2). MS: m/z: 214 (M+), 171 (M+-CH(CH3)), 169 (M+ - CO2H), 114 (M+ -CH3)2. A solution of L-valine (3) and L-aspartic acid (6) (Scheme 4), and the removal of the protecting methyl group to give the target compound (2). The cyclized compound (2) was obtained (Schwarz et al, 1957). On the other hand, the acid group of the valine was activated by reaction with N-hydroxy-succinimide in dioxane and in the presence of DCC to give compound (5). The two carboxy groups of L-aspartic acid were both protected as their methyl esters (Greenstein and Winitz, 1961). This was effected by careful addition of thionyl chloride to methanol, after which L-aspartic acid (6) was added. After stirring for 60 hours at room temperature, the required aspartate (7) was obtained in 63 % yield. The required dipeptide (8) was synthesized by reacting compound (5) with compound (7) in the presence of N-methylmorpholine, which was used as base in order to reduce the chance of racemization occurring at the chiral carbon °C (Cavelier et al, 2001). The first problem to be overcome was the development of an efficient approach for cyclization of dipeptide (8), in which the benzyl moiety was cleaved from its amide linkage. It was decided to use the acetic acid-catalyzed diketopiperazine synthesis (Suzuki et al, 1981). The approach involved cleavage with hydrogen bromide in acetic acid. The product was refluxed with stirring and the crystals were obtained by evaporation. The yield was poor and the n.m.r. spectrum showed that the carboxbenzoxyl group had not been totally cleaved. Our attention then turned to another approach which was palladium catalysed hydrogenolysis. A solution of dipeptide (8) in a mixture of butane-2-ol and acetic acid was hydrogenated in the presence of palladium on activated charcoal as a catalyst. The desired cyclic compound (10) was obtained in 92 % yield. The final stage involved the removal of the protecting methyl group to give the target compound (2). The cyclized compound (10) was dissolved in methanol and an aqueous solution of potassium hydroxide was added. On work-up, the desired piperezine (2) was obtained in 75 % yield (Scheme 1). All spectroscopic data, and elemental analysis confirm that the synthesized compound was 6-isopropyl-2,5-diketopiperazine-3-acetic acid. The antibacterial testing results of the compound (2), which were carried out at Glaxo are shown in Table 1. It exhibited no activity against the 27 bacterial and fungal strains that formed the test.
Table 1. Glaxo Group Research LTD: Microbiology Division (AM-6 Antimicrobial Screen)

| Organism                   | No. | Test | MICs µg/ml | Structure | Solubility: NaHCO₃ |
|----------------------------|-----|------|------------|-----------|-------------------|
| Staph. aureus 853E         | 1   | >500 | ≤ 0.06     | Ciromycin A |                 |
| Staph. aureus C864         | 2   | >500 | ≤ 0.06     |           |                   |
| Staph. epidermidis 887E    | 3   | >500 | ≤ 0.06     |           |                   |
| Micrococcus sp. 1810 E     | 4   | >500 | ≤ 0.06     |           |                   |
| Strept. faecalis 850       | 5   | >500 | 4          |           |                   |
| B. subtilis 841            | 6   | >500 | ≤ 0.06     |           |                   |
| B. cereus 173 BE           | 7   | >500 | 0.5        |           |                   |
| E. coli 851E               | 8   | >500 | 2          |           |                   |
| E. coli DC0 1850E          | 9   | >500 | 2          |           |                   |
| E. coli DC0 1852E          | 10  | >500 | 1          |           |                   |
| E. coli C2119              | 11  | >500 | 2          |           |                   |
| Ent. cloacae 1321E         | 12  | >500 | 4          |           |                   |
| K. aerogenes 1522E         | 13  | >500 | 1          |           |                   |
| K. pneumoniae 466          | 14  | >500 | 2          | T. mentag | 687E >500 1      |
| Serr. maraeascens 1324E    | 15  | >500 | 62         | T. verrucosum | 2126E >500 62   |
| Ps. aeruginosa 1371E       | 16  | >500 | >125       | T. rubrum | 1812E >500 0.5  |
| Ps. aeruginosa 165 SAI'    | 17  | >500 | 125        | A. niger | C116 >500 2     |
| C. albicans 316            | 18  | >500 | >125       |           |                   |
| C. albicans 120BE          | 19  | >500 | >125       |           |                   |
| Pr. Naraibalis 431E        | 20  | >500 | 4          |           |                   |
| Pr. morganii NCTC 235      | 21  | >500 | 31         |           |                   |
| Providence sp. 1497E       | 22  | >500 | 125        |           |                   |
| Bact. fragilis' 9326       | 24  | >500 | 125        |           |                   |
| Bact. fragilis' 1602E      | 25  | >500 | >125       |           |                   |
| C.L. perfringens 2045E     | 26  | >500 | 1          |           |                   |
| C.L. sporogenes 2052E      | 27  | >500 | 1          |           |                   |

When the data of the synthesized piperazine was compared with that of published cairomycin A, it showed that they are two different compounds. Cairomycin A had a melting point 110-112 °C, while the synthesized piperazine was melted at 222-224 °C. Infrared absorption of cairomycin A has a strong band at 1030, 1625 and 1735 cm⁻¹, whereas that of the synthesized compound showed strong absorption band at 1725 cm⁻¹ and broad absorption band at 1645 cm⁻¹. A clear difference was observed in their n.m.r. spectra (Table 2); cairomycin A was run in CDCl₃ while the synthesized piperazine was not soluble in CDCl₃ or (CD₃)₂CO, and was run in DMSO-d₆. In cairomycin A, a signal at δ 5.51 (triplet) was assigned to the methine proton of (CH-CH₃), whereas in our compounds this was at δ 4.11. Another difference which was most important was that while cairomycin A possessed potent activity against Gram-positive bacteria, the synthesized piperazine was biologically inactive. From the above evidence, it can be concluded that the structure of cairomycin A is not 6-isopropyl-2,5-diketopiperazine-3-acetic acid as proposed. Since acid hydrolysis of cairomycin A produced L-valine and L-aspartic acid, then they must be condensed together in another way to that proposed. We concluded that another possibility for its structure was one with β-lactam skeleton (11) and composed from two required amino acids valine and aspartic acid.
Thus, the β-lactam compound (11) became our target and which was hoped to be cairomycin A. The starting material chosen for this work was 4-vinylazetidin-2-one (15). This compound has already been synthesized by Stoodley (Brennan et al, 1980). The azetidinone (15) was obtained by the cycloaddition of chlorosulphonyl isocyanate (12) with 1,4-butadiene (13) to give N-sulphonyl chloride (14) which was reduced, without isolation, to 4-vinylazetidin-2-one (15) by treating with sodium sulphite. This method was improved, by addition of sodium carbonate to the reaction mixture to destroy the hydrogen chloride which was present in the chlorosulphonyl isocyanate (Scheme 2).

Moriconi has suggested (Moriconi and Meyer, 1971) a mechanism for the cycloaddition reaction, in which he proposed that the reaction starts with π complex formation and proceeds through the polar transition state.

The first problem to be overcome was the development of an efficient method for oxidation of the vinyl group. This oxidation has already been done (Pietsch, 1976); oxidation of vinylazetidin-one (15) with potassium permanganate in aqueous acetone provided 4-hydroxycarbonylazetidin-2-one (16) in 40% yield.

In order to develop an improved procedure to increase the yield of azetidinone (16), a variety of oxidizing agents was tried in a variety of solvents. The oxidizing agents used were: ozone (Vollhardt and Schore, 2007), potassium permanganate (Wang et al, 2015), pyridinium dichromate (Corey and Schmidt, 1979), and periodate plus permanganate (Lemienx and Rudloff, 1955); in a variety of solvents; methanol, dichloromethane, DMF, acetone or water. These attempts all were unsuccessful, and generally the yield was very poor. It was concluded that the problems arose in isolating the product because its solubility in the aqueous phase, while its solubility in the organic solvents was quite low. In an attempt to overcome the problem, it was decided to protect the β-lactam nitrogen. The protecting group chosen was tertbutyldimethylsilyl in the hope of producing an organic-soluble product.

N-silylation of the vinylazetidinone (15) with tert-butylidimethylchlorosilane led to azetidinone (17) in 89% yield. The azetidinone (17) was oxidized with potassium permanganate in acetone, at room temperature, to give the required N-protected azetidinone (18) in 85% as a white solid. In the next step the acid function in the compound (18) was activated by the N-hydroxy-succinamidine group. The required
azetidinone (19) was synthesized by reacting azetidinone (18) with N-hydroxysuccinimide in the presence of DCC, using dioxane as a solvent.

On the other hand, the acid site of the valine was protected with a benzyl group, while its amine site was temporarily protected as its p-toluene sulphonic salt in order to ultimately react the required amine site of valine with acid site of azetidinone (19) and to obtain the required peptide linkage.

The desired valine ester (20) was synthesized by reacting valine with benzyl alcohol in the presence of p-toluenesulphonic acid (Zervas et al, 1957). The resulting compound (20) was obtained in 83% as a white solid.

As this stage, both moieties of our target compound (21), azetidinone (19) and valine (20), are ready and the next step will be their reaction together in order to obtain the desired azetidinone (21). The required azetidinone (21) was thus obtained by reaction of the azetidinone (19) with valine ester (20) in 1,2-dimethoxyethane and the presence of N-methyl morhine.

It was noted, during purification of compound (21) by chromatography, that the partial desilylation took place and a mixture of N-protected and N-deprotected azetidinone was obtained. Therefore, the crude azetidinone (21) was treated with concentrated hydrochloric acid in ethanol to give the totally N-deprotected azetidinone (22) in 65% yield (from the azetidinone (19)) as a white solid.

The azetidinone (22) was next hydrogenated in the presence of palladium on activated charcoal as a catalyst to provide the desired target (11) in 97% yield.

The biological activity of compounds (11) against 27 bacterial and fungal strains were carried out at Glaxo. The testing results indicated that the synthesized β-lactam compound (11) was neither antibacterial nor β-lactamase inhibitory. The physical properties and spectroscopic data of the synthesized azetidinone (1) were compared to those published for cairomycin A (Shimi and Fathy, 1981).

Cairomycin A is described as a yellowish brown powder which melted at 110-112 °C, while the synthesized azetidinone was obtained as a white solid with melting point of 201-203 °C. Cairomycin A was freely soluble in chloroform, ethyl acetate, acetone and benzene; whereas the azetidinone (11) was insoluble in all but soluble in DMSO. The carbonyl group absorption of cairomycin A was at 1735 cm⁻¹, while the analogues β-lactam carbonyl absorbed at 1740 cm⁻¹.

A clear difference also observed when their n.m.r. spectra (Table 2) were compared, was the peak at δ 5.51 (triplet) which was proposed for methine proton of (C⁻H-CH₃), whereas in the β-lactam isomer this was δ 4.26. This difference in n.m.r. spectra was strong evidence to say that the suggested β-lactam structure for cairomycin A is doubtful. Another important difference between the isolated cairomycin A and the synthesized β-lactam compound (11) was the difference in their absorption of cairomycin A was at 1735 cm⁻¹, while the analogues β-lactam carbonyl absorbed at 1740 cm⁻¹.

As described before, cairomycin A possessed potent activity against Gram-positive bacteria, while the synthesized β-lactam compound was biologically inactive. From the evidence above, it would be concluded that the synthesized azetidinone (11) is not the structure of cairomycin A.

### Table 2. ¹H-NMR Spectra Comparison

| δ      | Mult. | Assig. | δ      | Mult. | Assig. | δ      | Mult. | Assig. |
|--------|-------|--------|--------|-------|--------|--------|-------|--------|
| 1.02   | d     | 2CH₃   | 0.83   | d     | CH₃    | 0.95   | d     | CH₃    |
| 1.52   | h     | Ha     | 0.91   | d     | CH₃    | 1.15   | d     | CH₃    |
| 3.04   | d     | CH₂    | 2.1    | m     | Ha     | 2.18   | m     | Ha'    |
| 4.25   | d     | Hb     | 2.65   | d     | Hb     | 2.76   | dd    | CH₂    |
| 5.51   | t     | He     | 2.7    | d     | CH₂    | 3.20   | dd    | CH₂    |
| 9.05   | br.   | 2NH    | 3.58   | m     | Hb     | 4.26   | m     | Hb' & He' |
| 9.2    | br.   | OH     | 4.11   | m     | Hb     | 8.3    | m     | Hb' & He' |
|        |       |        | 8.04   | s     | Hc     |        |       |        |
|        |       |        | 8.12   | s     | NH     |        |       |        |

### Table 3. Mass Spectra Comparison

| m/z   | %  | m/z   | %  | m/z   | %  |
|-------|----|-------|----|-------|----|
| 214 (M⁺) | 15 | 214 (M⁺) | 50 | 214 (M⁺) | 20 |
| 144    | 87 | 172   | 66 | 172   | 34 |
| 111    | 100| 126   | 58 | 151   | 54 |
| 99     | 100| 112   | 100| 135   | 63 |
| 84     | 73 | 88    | 40 | 126   | 27 |
| 70     | 63 | 72    | 65 | 100   | 11 |
| 57     | 30 | 60    | 18 | 88    | 100 |
| 55     | 25 | 55    | 62 | 74    | 25 |
| 43     | 79 | 43    | 45 | 45    | 7  |
| 41     | 24 | 29    | 58 | 28    | 31 |

### 4. CONCLUSION

The synthesis of proposed structure of cairomycin A, 6-isopropyl-2,5-diketopiperazine-3-acetic acid (2), and its β-lactam isomer (11) where studied.
When the physical properties, spectroscopic data and biological activities of both synthesized compounds (2) and (11) where compared with those for cairomycin A, it was concluded that the structure of cairomycin A neither 6-isopropyl-2,5-diketopiperazine-3-acetic acid (2) nor its β-lactam analogues (11).

The n.m.r. cairomycin A was run in CDCl₃, while the synthesized compounds were not soluble in CDCl₃ and were run in DMSO-d₆.

It has been reported that the Hc in the cairomycin A had a signal at δ 5.51 which would be too high for such a type of proton. An N.O.E. difference experiment in which Hc was irradiated showed equal effects on both H₂ Protons indicating that these had free rotation relative to Hc.

According to the above information it was concluded that the methine group (CHc) in the cairomycin A, might be surrounded by one of neither (2) nor (11), it was concluded that the methine group (CHc) in the cairomycin A, might be surrounded by one of the following proposed groups, to have such chemical shift (δ 5.51):

i) An amide group and an oxygen atom;
ii) Two amide groups;
iii) An amide and carbonyl group, and a sulfur atom.

Further investigation of this problem would however, require a pure sample of the substance designated cairomycin A.

REFERENCES

Abraham, W. R. (2005). Controlling pathogenic gram-negative bacteria by interfering with their biofilm formation. Drug Design Reviews-Online, 2(1), 13-33.

Borthwick, A. D. (2012). 2, 5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Chemical reviews, 112(7), 3641-3716.

Brennan, J., Richardson, G., & Stoddley, R. J. (1980). Synthesis of 7-oxo-3-oxa-1-azacyclo [3.2.0] heptane-2-carboxylates: analogues of clavulanic acid. Journal of Chemical Society, Chemical Communications, (2), 49a-49a.

Cavilier, F., Girand, M., Bernard, M., and Martinez, J. (2001). Original and General Strategy of Dimerization of Bioactive Molecules in Peptides: The Wave of the Future; Lebl, M., Houghten, R.A., Eds.; American Peptide society; San Diego, 152-155.

Corey, E. J., & Schmidt, G. (1979). Studies on the total synthesis of rifamycin. A method for the stereospecific synthesis of the carbonyl-conjugated 1,3-diene unit [C (15) to C (20)]. Tetrahedron Letters, 20(25), 2317-2320.

Delaforge, M., Bouillé, G., Jaouen, M., Jankowski, C. K., Lamouroux, C., & Bensoussan, C. (2001). Recognition and oxidative metabolism of cyclodepsipeptides by hepatic cytochrome P450. Peptides, 22(4), 557-565.

Dinsmore, J.C., and Beshore, D.C. (2002). Recent Advances in the Synthesis of Diketopiperazines, Tetrahedron, 58(17), 3297-3312.

Fischer, P. M. (2003). Diketopiperazines in peptide and combinatorial chemistry. Journal of Peptide Science: an official publication of the European Peptide Society, 9(1), 9-35.

Greenstein, J.P. and Winitz, M. (1961) Chemistry of the Amino Acids. John Wiley & Sons, New York, 763.

Houston, D. R., Synstad, B., Eljink, V. G., Stark, M. J., Eggleston, I. M., & Van Aalten, D. M. (2004). Structure-based exploration of cyclic dipeptide chitinase inhibitors. Journal of medicinal chemistry, 47(23), 5713-5720.

Kumar, A., Singh, M., & Chauhan, V.S. (1985). Synthesis of cairomycin A. The Journal of Antibiotics, 38(10), 1420-1422.

Lemieux, R. U., & Rudloff, E. V. (1955). Periodate-permanganate oxidations: I. Oxidation of olefins. Canadian Journal of Chemistry, 33(11), 1701-1709.

Moriconi, E. J., & Meyer, W. C. (1971). Reaction of dienes with chlorosulfonyl isocyanate. The Journal of Organic Chemistry, 36(19), 2841-2849.

Nicholson, B., Lloyd, G. K., Miller, B. R., Palladino, M. A., Kiso, Y., Hayashi, Y., & Neuteboom, S. T. (2006). NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-cancer drugs, 17(1), 25-31.

O’Neill, J. C., & Blackwell, H. E. (2007). Solid-phase and microwave-assisted syntheses of 2, 5-diketopiperazines: small molecules with great potential. Combinatorial chemistry & high throughput screening, 10(10), 857-876.

Pietsch, H. (1976). Synthese von S-Asparyl-3-phenylalaninemethylster (aspartam) aus S-4-vinylazetidin-2-on. Tetrahedron Letters, 17(45), 4053-4056.

Schwarz, H., Bumpus, F. M., & Page, I. H. (1957). Synthesis of a Biologically Active Octapeptide Similar to Natural Isoleucine Angiotonin Octapeptide1. Journal of the American Chemical Society, 79(21), 5697-5703.

Shimi, I.R., and Fathy, Sh. (1981). Isolation of Cairomycins A and C, Antimicrobial Agents and Chemotherapy, 19(6), 941-944.

Sinha, S., Srivastava, R., De Clercq, E., & Singh, R. K. (2004). Synthesis and antiviral properties of arabino and ribonucleosides of 1, 3-dideazadenine, 4-nitro-1, 3-dideazadenine and diketopiperazine. Nucleosides, Nucleotides and Nucleic Acids, 23(12), 1815-1824.

Sun, X., Rai, R., Mackereil Jr, A. D., Faden, A. I., & Xue, F. (2014). Facile one-step synthesis of 2, 5-diketopiperazines. Tetrahedron Letters, 55(11), 1905-1908.

Suzuki, K., Sasaki, Y., Endo, N. O. B. U. Y. O. S. H. I., & Mihara, Y. U. I. C. H. I. (1981). Acetic acid-catalyzed diketopiperazine synthesis. Chemical and Pharmaceutical Bulletin, 29(1), 233-237.

Vollhardt, K., and Schoe, N. (2007). Organic Chemistry: Structure and Function, 5th ed. New York, NY: W.H. Freeman and Company.

Wang, C., Zong, L., & Tan, C. H. (2015). Enantioselective oxidation of alkenes with potassium permanganate catalyzed by chiral dicaticonic bisguanidinium. Journal of the American Chemical Society, 137(33), 10677-10682.

Zervas, L., Winitz, M., & Greenstein, J. P. (1957). Studies on arginine peptides. I. Intermediates in the synthesis of N-terminal and C-terminal arginine peptides. The Journal of Organic Chemistry, 22(11), 1515-1521.